Eloralintide: The Non-GLP-1 Weight-Loss Peptide
Eli Lilly's selective amylin receptor agonist produced up to ~20% weight loss over 48 weeks in Phase 2 — through a pathway entirely separate from Ozempic and Mounjaro. Here's what the trials actually show.
How It Works
Eloralintide is a selective amylin receptor agonist — a synthetic analog of amylin, a hormone co-secreted with insulin by pancreatic β-cells. It works through a pathway distinct from GLP-1 drugs like semaglutide and tirzepatide.
Amylin signaling slows gastric emptying, suppresses glucagon, and promotes meal termination through central brain pathways — reducing food intake and driving weight loss.
In vitro, eloralintide preferentially activated the human AMY1 receptor (~12-fold over the calcitonin receptor). In rats it caused significantly less conditioned taste avoidance than cagrilintide — a preclinical tolerability signal.
Its pharmacokinetics support once-weekly subcutaneous dosing. In diet-induced obese rats, the weight lost came primarily from fat mass rather than lean tissue.
What the Data Shows
Key Takeaways
- Eloralintide (LY3841136) is an investigational, selective, long-acting amylin receptor agonist being developed by Eli Lilly for obesity, dosed once weekly by subcutaneous injection.
- In a 48-week Phase 2 trial of 263 adults, it produced dose-dependent mean weight loss of roughly 9% (1 mg) to 20% (9 mg) versus −0.4% for placebo.
- It acts through the amylin pathway — satiety and slowed gastric emptying — a mechanism distinct from GLP-1 drugs like semaglutide and tirzepatide.
- Preclinically it is AMY1-receptor-selective and caused less taste aversion than cagrilintide, hinting at a possible tolerability edge.
- Nausea and fatigue were the most common side effects and increased with dose (nausea reached ~64% in the 6 mg group).
- Whether its receptor selectivity translates into a real tolerability advantage over other amylin analogs in humans is not yet established.
- There are no Phase 3 results, no long-term (multi-year) safety or durability data, and no approval by the FDA or any regulator.
- How it compares head-to-head with GLP-1/GIP drugs such as tirzepatide or retatrutide on weight loss or side effects is unknown.
- Whether weight is regained after stopping — as seen with GLP-1 drugs — has not been studied for eloralintide.
- It is NOT available to buy anywhere: it is a clinical-trial compound, not a marketed medicine or a research chemical.
Frequently Asked Questions
What is eloralintide?
Eloralintide (development code LY3841136) is an investigational peptide from Eli Lilly being studied for weight loss. It is a selective, long-acting amylin receptor agonist given as a once-weekly subcutaneous injection — not a GLP-1 drug.
Is eloralintide a GLP-1 drug like Ozempic or Mounjaro?
No. Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) act on GLP-1 (and GIP) receptors. Eloralintide activates the amylin pathway instead, which controls satiety and gastric emptying through different signaling — which is why it is described as a "non-GLP-1" weight-loss peptide.
How much weight loss did eloralintide produce?
In a 48-week Phase 2 trial of 263 adults with obesity or overweight, mean weight loss ranged from about 9% at 1 mg to 20% at 9 mg, compared with 0.4% on placebo. These are trial averages, not guaranteed individual results.
Is eloralintide safe? What are the side effects?
In trials the most common side effects were nausea and fatigue, both increasing with dose (nausea reached about 64% in the 6 mg group). Long-term safety is not yet known — it has not completed Phase 3 or been approved.
Can I buy eloralintide?
No. Eloralintide is an experimental drug still in clinical trials and is not sold as a prescription medicine or as a research chemical. Any product marketed as "eloralintide" for sale should be treated with extreme caution.
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
📚 Related HighPeptides Research
Peer-Reviewed References
Educational purposes only. Not medical advice.
Eloralintide is an investigational drug in clinical trials — not approved by the FDA or any regulator, and not available for purchase. Nothing here is a recommendation to obtain or use it.